PRP for Female Sexual Function: What Does the Evidence Say?

Platelet-rich plasma (PRP) is increasingly being explored in women’s health, particularly for concerns such as sexual dysfunction, vaginal dryness, and reduced sensitivity.

You may have seen this treatment referred to online as the “O-Shot”. While that term is commonly used in media and marketing, it is not a generic medical term and does not reflect a standardised, evidence-based procedure.

So what does the science actually say about PRP in this context?

What is PRP and How is it Used in Intimate Health?

PRP is derived from a patient’s own blood and contains a high concentration of platelets and growth factors. These include:

• Platelet-derived growth factor (PDGF)

• Transforming growth factor beta (TGF-β)

• Vascular endothelial growth factor (VEGF)

These mediators are thought to promote:

• Angiogenesis

• Collagen synthesis

• Tissue regeneration

In gynaecological applications, PRP is typically injected into the vulvo-vaginal area and surrounding structures, with the aim of improving tissue quality and function.

Proposed Indications

PRP-based vaginal treatments have been explored for:

• Female sexual dysfunction

• Genitourinary syndrome of menopause (GSM)

• Vaginal atrophy

• Dyspareunia

• Stress urinary incontinence

The rationale is biologically plausible, particularly in conditions where tissue integrity and vascularity are compromised.

What Does the Evidence Show?

Early Data: Promising but Limited

Small observational studies and pilot trials have reported improvements in:

• Sexual satisfaction scores

• Vaginal lubrication

• Symptom burden

Some studies also suggest potential benefits in urinary incontinence and menopausal symptoms.

However, these findings are largely based on:

• Small sample sizes

• Non-randomised designs

• Subjective outcome measures

  

Higher-Level Evidence: Still Lacking

Recent reviews, including the study you referenced, highlight several key limitations:

• Lack of large, well-designed randomised controlled trials

• Significant heterogeneity in injection protocols

• Variable outcome measures across studies

At present, there is no high-quality evidence confirming consistent clinical efficacy for PRP in female sexual dysfunction.

Safety Profile

PRP is autologous, which reduces the risk of allergic or immunogenic reactions.

Reported side effects are generally mild:

• Temporary discomfort

• Bruising

• Localised swelling

That said, long-term safety data remains limited, particularly with repeated treatments.

Clinical Perspective

From an evidence-based standpoint, PRP for intimate health sits in an emerging but not yet established category.

It is:

• Biologically plausible

• Supported by early-stage data

• Not currently a first-line or guideline-supported treatment

Patients presenting with these concerns should still be assessed holistically, with consideration of:

• Hormonal factors

• Pelvic floor dysfunction

• Psychosexual components

• Evidence-based medical therapies

  
  

Key Takeaways

• PRP for intimate health is an emerging regenerative treatment

• It is often marketed under branded names, but lacks standardisation

• Early results are promising, but evidence remains limited

• It should not replace established, evidence-based treatments

  
  

Final Thoughts

Regenerative medicine is expanding rapidly within aesthetics and beyond. While innovation is important, clinical practice must remain grounded in evidence, particularly in sensitive areas such as intimate health.

At present, PRP-based treatments should be approached with cautious optimism, with clear patient counselling and realistic expectations..